NewsSOS
Baron Capital sold its position in Apogee Therapeutics, Inc. (NASDAQ: APGE) after AbbVie Inc.
agreed in June to acquire the clinical-stage biotechnology company at $135.11 per share, a 49.5% premium to the prior day's close, the firm's Baron Health Care Fund disclosed in its second-quarter 2026 investor letter.
The acquisition and Baron's exit The deal prompted a full exit. Baron Health Care Fund stated in its Q2 2026 letter that it sold Apogee Therapeutics following the announcement the company was being acquired by AbbVie.
Apogee closed at $134.19 on August 4, 2026, just below the offer price.
Keep reading